We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Ingestible Scouring Sponge Identifies Esophageal Abnormities

By HospiMedica International staff writers
Posted on 12 Feb 2019
Print article
Image: An expandable polyurethane sphere helps detect esophageal cancer (Photo courtesy of CapNostics).
Image: An expandable polyurethane sphere helps detect esophageal cancer (Photo courtesy of CapNostics).
A minimally invasive esophageal cytology sampling device in the form of a small sponge can aid early diagnosis of Barrett's esophagus (BE) and esophageal cancer in high-risk patients.

The CapNostics (Doylestown, PA, USA) EsophaCap is a swallowable device made of medical grade foam compressed into an ingestible capsule that is designed for deployment within 10 minutes. Once swallowed, the gelatin coating on the capsule dissolves in under three minutes, causing the polyurethane sponge, which is attached to a string, to expand into a sphere two centimeters in diameter. The string is then gently pulled back through the mouth; as the sponge makes its way up, it collects genetic material along the length and breadth of the esophagus.

When the sponge reaches the top of the esophagus it is withdrawn, laden with DNA material that is subsequently extracted using a technique known as methylation on beads (MOB). The beads bind to the DNA, which can be easily collected and subsequently analyzed by a biomarker panel so as to identify the four methylation biomarkers that appear to best predict which patients with BE might progress to neoplasia. In a study published on January 22, 2019, in Clinical Cancer Research, EsophaCap showed a diagnostic accuracy of 86.7%, a sensitivity of 78.6%, and a specificity of 92.8% for BE detection.

“Early detection is the whole ballgame when it comes to esophageal cancer. This novel sponge device can be administered by anyone with minimal training, ideally in any physician's office, where the procedure could be routinely performed,” said senior study author Professor Stephen Meltzer, MD, of Johns Hopkins University (JHU, Baltimore, MD, USA). “This is cheaper, easier and safer than endoscopy. Nor does the EsophaCap have to be protected against contamination from DNA material as the device passes through normal esophageal tissue in smokers.”

Barrett's esophagus refers to an abnormal change (metaplasia) in the cells of the lower portion of the esophagus, when the normal squamous epithelium lining is replaced by goblet cells, which are usually found lower in the gastroitestinal tract. The medical significance of BE is its strong association with esophageal adenocarcinoma, a particularly lethal form of cancer.

Related Links:

Print article



view channel

44th IHF World Hospital Congress Presents Over 60 Plenary Sessions and 200 Renowned Speakers Across Four-Day Event

The 44th World Hospital Congress organized by The International Hospital Federation (Geneva, Switzerland) will bring together more than 200 healthcare experts, leading industry thinkers, and best practice... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.